Drugging cancer genomes

Journal name:
Nature Reviews Drug Discovery
Year published:
Published online

A recent landmark analysis compared genome-wide mutations and associated 'omics' features for 3,281 tumours across 12 human cancer types. There is a clear need for objective target assessment and prioritization by the drug discovery community to make the best use of such vast amounts of data.


  1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333339 (2013).
  2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 15461558 (2013).
  3. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177183 (2004).
  4. Patel, M. N. et al. Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 3550 (2013).
  5. Halling-Brown, M. D. et al. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947D956 (2012).

Download references

Author information


  1. Paul Workman and Bissan Al-Lazikani are at the Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.

Competing interests statement

The authors work at The Institute of Cancer Research, London, UK, which has a commercial interest in the discovery and development of anticancer drugs.

Corresponding authors

Correspondence to:

Author details

Supplementary information

PDF files

  1. Supplementary information S1 (box) (1.96 MB)

    Objective analysis of cancer genes

Additional data